Fenggong Wang

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang et al. · Annals of Oncology · 2019 · 466 citations · Full text

<scp>pyDarwin</scp>: A Machine Learning Enhanced Automated Nonlinear Mixed‐Effect Model Selection Toolbox

Xinnong Li, Mark Sale, Keith Nieforth et al. · Clinical Pharmacology & Therapeutics · 2023 · 11 citations · Full text